The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMcbride Regulatory News (MCB)

Share Price Information for Mcbride (MCB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 111.00
Bid: 109.50
Ask: 111.50
Change: 1.50 (1.37%)
Spread: 2.00 (1.826%)
Open: 110.00
High: 112.00
Low: 110.00
Prev. Close: 109.50
MCB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Refinancing on improved terms

27 Jun 2017 07:00

RNS Number : 2177J
McBride PLC
27 June 2017
 

27 June 2017

 

McBride plc

 

Refinancing on improved terms

 

McBride plc ("the Group"), the leading European manufacturer and supplier of Co-manufactured and Private Label products for the Household and Personal Care market, today announces the refinancing of the Group in further support of the Group's Repair, Prepare, Grow strategy.

 

The Group has secured replacement banking facilities from a panel of international banks and using these increased facilities will repay its US Private Placement Notes ("USPP"). These actions will lower the cost of the Group's debt financing from the financial year starting on 1 July 2017 by approximately £2.0m per year.

 

 

Replacement Bank Facilities

 

The existing EUR 140m multi-currency revolving credit facility ("RCF") has been increased to a five year EUR 175m facility with a maturity of June 2022.

 

Features of the replacement facilities include:

 

- a EUR 175m RCF of which approximately EUR 70m will be drawn, providing the Group with significant committed funding headroom

- a 5 bps reduction in both margin and non-utilisation fees

- the addition of further borrowing entities and currencies, increasing flexibility going forward

- a EUR 75m uncommitted accordion feature will provide additional facilities for potential future acquisitions in support of the Grow phase of our strategy

 

The bank facilities are provided by a syndicate of HSBC, KBC, Bayern LB, BNP Paribas and Barclays.

 

US Private Placement Notes

 

The existing $50m 5.51%1 2020 USPP and $40m 5.38%1 2022 USPP will be repaid in full by drawing on the increased RCF.

 

Under the terms of the USPP arrangements, the Group will pay a 'make-whole' payment to existing USPP note-holders of approximately £11m2. At the same time the Group will close out the Euro/Dollar cross-currency interest rate swaps relating to the existing USPP notes which have a current mark-to-market net value of approximately £11m3 in favour of the Group.

 

Financing charges

 

Based on the current level of borrowings and interest swap rates, and taking into consideration the amortisation of initial fees, the Group's pro forma annual underlying finance charge will, over a full year, reduce by approximately £2m4 per annum. The Group's overall ongoing average cost of debt, after the repayment of the USPP, will reduce by approximately 310bps 4 to 150bps.

 

The 'make whole' payment to USPP note-holders will be treated for the Group's financial statements for the 12 months to 30 June 2017 as an exceptional finance charge. The total exceptional finance charge associated with this transaction will be approximately £13m comprising the make whole payment and additional USPP closure costs.

 

Net Debt

 

Following completion of all the transactions surrounding this change, which are expected by 30 June 2017, the impact on the Group's current net debt level will remain broadly unaffected.

 

 

Chris Smith, Chief Financial Officer of McBride, commented:

 

"As we prepare for the Grow phase of our strategy, we have secured an improvement in the cost, flexibility and duration of our banking facilities. The completion of this exercise represents another important milestone in the delivery of Repair, Prepare and Grow and reflects the strong ongoing support from our chosen banks."

 

 

Notes

1 - Adjusted for the impact of cross currency swap agreements.

2 - Will be treated as exceptional finance costs. Value estimated as at 23 June 2017.

3 - Will be treated as a movement on the derivative already reported in our income statement. Value estimated as at 23 June 2017.

4 - As compared to the position at 30 June 2016

 

 

For further information please contact:

 

McBride plc

Chris Smith, Chief Financial Officer

0161 203 7570

FTI Consulting

Ed Bridges, Nick Hasell

020 3727 1017

 

Note: This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation which came into effect on 3 July 2016.

 

-Ends-

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFFMPTMBITBIR
Date   Source Headline
8th Apr 202411:24 amRNSHolding(s) in Company
8th Apr 202411:22 amRNSHolding(s) in Company
5th Apr 20249:53 amRNSHolding(s) in Company
28th Mar 20243:20 pmRNSDirector/PDMR Shareholding
25th Mar 20241:52 pmRNSDirector/PDMR Shareholding
13th Mar 20247:00 amRNSCapital Markets Day
28th Feb 20242:30 pmRNSDirector/PDMR Shareholding
27th Feb 20247:00 amRNSHalf-year Report
16th Jan 20247:00 amRNSTrading Update
13th Dec 20231:47 pmRNSDirector/PDMR Shareholding
20th Nov 20235:55 pmRNSDirector/PDMR Shareholding
20th Nov 20235:39 pmRNSResult of AGM
20th Nov 20237:00 amRNSAGM Trading Update
25th Oct 202310:22 amRNSTermination of ‘upside sharing’ mechanism
19th Oct 20237:00 amRNSTrading Update
17th Oct 20235:42 pmRNSPosting of ARA and Notice of AGM
4th Oct 20235:24 pmRNSVesting of RSU Awards
29th Sep 20237:00 amRNSDirector/PDMR Shareholding
22nd Sep 20235:33 pmRNSDirector/PDMR Shareholding
21st Sep 202310:54 amRNSDirector/PDMR Shareholding
19th Sep 20237:00 amRNSFinal Results
14th Jul 20237:00 amRNSFull year trading update
13th Jun 20237:00 amRNSDirector/PDMR Shareholding
31st May 20235:31 pmRNSDirectorate Change
25th May 20239:38 amRNSDirector Declaration
2nd May 20237:00 amRNSDirector/PDMR Shareholding
25th Apr 20237:00 amRNSTrading Update
11th Apr 20232:08 pmRNSDirector/PDMR Shareholding
3rd Apr 20232:39 pmRNSDirector/PDMR Shareholding
31st Mar 202312:27 pmRNSDirector/PDMR Shareholding
21st Mar 20235:59 pmRNSDirector/PDMR Shareholding
28th Feb 20237:00 amRNSHalf-year Report
1st Feb 20234:40 pmRNSSecond Price Monitoring Extn
1st Feb 20234:35 pmRNSPrice Monitoring Extension
1st Feb 20238:46 amRNSDirector Declaration
17th Jan 20237:00 amRNSTrading Update
11th Jan 20239:01 amRNSDirector Declaration
22nd Dec 20224:23 pmRNSDirector/PDMR Shareholding
13th Dec 20222:51 pmRNSDirector/PDMR Shareholding
16th Nov 20224:42 pmRNSAGM Statement
16th Nov 20227:00 amRNSAGM Trading Update
17th Oct 20227:00 amRNSAnnual Report 2022 and Annual General Meeting 2022
5th Oct 20225:55 pmRNSDirector/PDMR Shareholding
3rd Oct 20225:07 pmRNSRedemption of B Shares
29th Sep 202212:49 pmRNSFinal Results
29th Sep 202211:51 amRNSAmended Financing Agreement
29th Sep 20227:00 amRNSPreliminary results timing
6th Sep 20222:51 pmRNSBoard Update
30th Aug 20224:35 pmRNSPrice Monitoring Extension
25th Aug 20226:22 pmRNSCorrection - Result of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.